CONSTANT LEVERAGE LONG - NOVO-NORDISK B | Real-time Euronext Paris 04:43:16 2024-05-23 am EDT | ||
| 4.91 EUR | +16.35% |
|
| Current month | +7.38% | ||
| 1 month | +20.23% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 4.91 | +16.35% |
| 24-05-22 | 4.22 | -3.76% |
| 24-05-21 | 4.385 | +27.47% |
| 24-05-17 | 3.44 | -12.91% |
| 24-05-16 | 3.95 | -4.93% |
Real-time Euronext Paris
Last update May 23, 2024 at 04:43 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| 5FLMB | |
| ISIN | NLBNPNL2IDX9 |
| Date issued | 2023-09-20 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.845 € |
|---|---|
| Lowest since issue | 0.496 € |
| Spread | 0.08 € |
| Spread % | 1.60% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
923
DKK
Average target price
909.2
DKK
Spread / Average Target
-1.49%
- Stock Market
- Certificates
- 5FLMB Certificat
